Non-responders to previous treatment for hepatitis C

Minerva Gastroenterologica e Dietologica

Volumn 51, Issue 1, 2005, Pages 47-54

  Gross, J B ^a  

^a MAYO CLINIC   (United States)

Author keywords

Drug resistance, viral; Hepatitis C, complications; Hepatitis C, drug therapy

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; AMANTADINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CAMOSTAT MESILATE; CILUPREVIR; COLCHICINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; ETANERCEPT; GAMMA1B INTERFERON; GLIOTOXIN; GLYCYRRHIZIC ACID; INTERFERON; OLIGONUCLEOTIDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PENTOXIFYLLINE; RAPAMYCIN; RIBAVIRIN; RIBOZYME; SILYMARIN; VIRUS ENZYME; VIRUS RNA; XIAO CHAI HU TANG; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; HEPATITIS C; HUMAN; LIVER FIBROSIS; NAUSEA AND VOMITING; NONHUMAN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; HEPATITIS C VIRUS; MULTICENTER STUDY; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; CONTROLLED CLINICAL TRIALS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERONS; MULTICENTER STUDIES; POLYETHYLENE GLYCOLS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 19444376820     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
2. Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002;347:975-82.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004;140:346-55.
4. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
5. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132:517-24.
6. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003;38:493-502.
7. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
8. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
9. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370-81.
10. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002;36:S128-34.
11. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
12. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
13. Cheng SJ, Bonis PAL, Lau J Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001;33:231-40.
14. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon. JAMA 2001;285:193-9.
15. Gonzalez HJ, Ho SB, Gross JB, Peine C, McKee D, Smith T et al. Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-a2b for initial treatment of chronic hepatitis C. Dig Dis Sci 2002;47:784-92.
16. Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F et al. Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol 2003;39:606-13.
17. Shiffman ML, DiBisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126: 1015-23.
18. Jacobson I, Ahmed F, Russo MW, Brown RS, Jr, Lebovics E, Min A et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior non-responders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results. Gastroenterology 2003;124:A714.
19. Gross JB, Therneau TM, Johnson SM, Kwo PY, Afdhal NH, Flamm SL et al. The RENEW trial: a national, multicenter study of high-dose peginterferon alfa-2b + ribavirin for non-responders with hepatitis C. Hepatology 2003;38:312A.
20. Kaiser S, Hass H, Gregor M. Successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon and ribavirin using daily consensus interferon and ribavirin. Hepatology 2004;40:241A.
21. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-46.
22. Leevy C II, Chalmers C, Blatt LM. Comparison of African American and non African American patient end of treatment response for PEG-IFN alpha 2b + weight-based ribavirin nonresponders retreated with IFN alfacon-1 + weight-based ribavirin. Hepatology 2004;40:240A.
23. Afdhal NH, Freilich B, Levine R, Black M, Brown R Jr, Monsour H et al. Colchicine versus PEG-Intron long-term (COPILOT) trial: interim analysis of clinical outcomes at year 2. Hepatology 2004;40:239A.
24. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000;118:655-60.
25. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003;38:859-68.
26. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9.
27. Zein NN. A phase II randomized, double-blind, placebo controlled study of tumor necrosis factor antagonist (etanercept, Enbrel) as an adjuvant to interferon and ribavirin in naïve patients with chronic hepatitis C. Hepatology 2002;36:304A.
28. Albanis E, Safadi R, Friedman SL. Treatment of hepatic fibrosis: almost there. Curr Gastroenterol Reports 2003;5:48-56.
29. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Sem Liv Dis 2001;21:437-51.
30. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001;121:148-55.
31. Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001;35:376-85.
32. Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesylate, via reduced generation of active TGF-β. Gastroenterology 2001;120: 1784-800.
33. Wright M, Issa R, Smart DE, Trim N, Murray GI, Primrose JN et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001;121:685-98.
34. Parsons CJ, Bradford BU, Pan CQ, Cheung E, Schauer M, Knorr A et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 2004;40:1106-15.
35. McHutchison JG, Dev AT. Future trends in managing hepatitis C. Gastroenterol Clin North Am 2004;3:23-9.
36. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347-55.
37. Afdhal NH, Godofsky E, Dienstag J, Rustgi V, Schick L, McEniry D et al. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 2004;40:726A.